Previous close | 136.34 |
Open | 136.66 |
Bid | 131.71 x 800 |
Ask | 143.56 x 1100 |
Day's range | 135.26 - 137.46 |
52-week range | 119.59 - 145.58 |
Volume | |
Avg. volume | 1,009,135 |
Market cap | 15.262B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 18.49 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.00 (2.18%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | N/A |
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.